ORODISPERSIBLE TABLETS MARKET ANALYSIS

Market News

Global Orodispersible Tablets Market- Recent Developments

New Product Launches

1. On August 4, 2023, Biogen, one of the leading global biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression (PPD). URZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD.
2. In November 2022, Shionogi & Co., Ltd., a Japan-based pharmaceutical company, announced that Xocova, a novel anti-SARS-CoV-2 drug for COVID-19, obtained emergency regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the indication of SARS-CoV-2 infection. Xocova is an oral antiviral agent that is administered once daily for five days that suppresses the replication of SARS-CoV-2.
3. In December 2022, Gilead Sciences, Inc., a biopharmaceutical company, announced that Sunlenca (lenacapavir) in combination with other antiretroviral(s) (ARV) had been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection. Sunlenca (300 mg tablet and 463.5 mg/1.5 mL injection) is a first-in-class, long-acting HIV capsid inhibitor approved in the U.S., the U.K., Canada and the European Union, for the treatment of HIV infection.
4. In September 2021, AbbVie Inc., one of the global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved QULIPTA (atogepant) for the preventive treatment of episodic migraine in adults. QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of migraine.

Acquisition and partnerships

1. On March 30, 2023, GSK plc., one of the global pharmaceutical company, announced t that it had signed an exclusive licence agreement for Brexafemme (ibrexafungerp tablets) a U.S. FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) with SCYNEXIS, a pharmaceutical company
2. In September 2022, Emergent BioSolutions Inc., a multinational specialty biopharmaceutical company, announced that it had completed its acquisition of exclusive worldwide rights to TEMBEXA, oral antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox, from Chimerix, a biotechnology company
3. In December 2021, Pfizer Inc., one of the global pharmaceutical company, and Arena Pharmaceuticals, Inc., a biopharmaceutical company, announced that the companies had entered into a definitive agreement, under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Arena’s portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases.
4. Aquestive Therapeutics Partners with Sunovion: In December 2020, Aquestive Therapeutics, a specialty pharmaceutical company, entered into a partnership with Sunovion Pharmaceuticals, a part of Sumitomo Pharma America, Inc., a science-based, technology-driven biopharmaceutical company. The collaboration aimed to develop and commercialize an oral film formulation of an undisclosed central nervous system (CNS) drug, potentially including orodispersible tablets.